Annual report pursuant to Section 13 and 15(d)

Nature of Business and Significant Accounting Policies (Narrative) (Details)

v3.22.2.2
Nature of Business and Significant Accounting Policies (Narrative) (Details)
12 Months Ended
Sep. 30, 2022
USD ($)
country
segment
item
Sep. 30, 2021
USD ($)
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]    
Number of countries in which entity operates | country 150  
Number of countries in which entity markets directly to consumers | country 22  
Number of primary financial institutions where cash is maintained | item 3  
Number of reporting units | item 2  
Number of operating segments | segment 1  
Capitalized nonrefundable advance payments $ 0 $ 0
Research and development 70,646,103 32,694,405
Assets 136,126,017 178,146,723
Foreign currency gains (losses) 0 0
Sabizabulin [Member]    
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]    
Production costs for pre-launch inventory included in research and development expense 18,600,000  
Accumulated Foreign Currency Translation Loss [Member]    
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]    
Accumulated other comprehensive income (600,000) (600,000)
Outside United States [Member]    
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]    
Assets $ 10,800,000 $ 8,500,000